Comparative study of colistin methanesulfonate and colistin sulfate/polymyxin B in the treatment of ceftazidime-avibactam resistant Gram-negative bacilli infections

Abstract

Objective: To evaluate the clinical efficacy of different species of polymyxin drugs in the treatment of Carbapenem-Resistant Gram-negative bacilli (CR-GNB) resistant to ceftazidime-avibactam (CZA).

Methods: Patients infected by CR-GNB strains and treated with polymyxin drugs were selected and divided into colistin methanesulfonate (CMS) group and colistin sulfate/polymyxin B (CSPB) group to observe clinical efficacy and safety.

Results: 65 patients were eventually included (CMS group, n = 29; CSPB group, n = 36). The clinical efficacy, microbiological eradication rate and 28-day mortality between the two groups were similar, with no statistical significance (51.72% vs. 50.00%, p = 0.890; 55.17% vs. 52.78%, p = 0.847; 17.24% vs. 25.00%, p = 0.449). With regard to renal safety, the incidence of acute kidney injury (AKI) in the CMS group was significantly higher than that in the CSPB group (34.48% vs. 5.56%, p = 0.003). Among them, the incidence of AKI grade 3 in the CMS group tended to be higher than that in the CSPB group (24.14% vs. 5.56%, p = 0.066).

Conclusion: The results based on small sample size from a single center showed that clinical response to the treatment of ceftazidime-avibactam resistant Gram-negative bacillus infections is similar for CMS and Colistin Sulfate/Polymyxin B, but the nephrotoxicity of CMS is greater than that of polymyxin sulfates.

Keywords

Ceftazidime-avibactam resistant / Gram-negative bacteria / Polymyxin / Colistin / Clinical efficacy / Safety

References

[1] Zeng M, Xia J, Zong Z, et al. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J Microbiol Immunol Infect. 2023 Feb 18. S1684-1182(23)00036-1.

[2] Sternbach N, Leibovici Weissman Y, Avni T, et al. Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis. J Antimicrob Chemother. 2018 Aug 1;73(8):2021–2029.

[3] Chen Y, Huang HB, Peng JM, et al. Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant Enterobacterales bloodstream infection: a systematic review and meta-analysis. Microbiol Spectr. 2022 Apr 27;10(2):e0260321.

[4] Bacterial resistance surveillance results in the China antimicrobial surveillance network (CHINET) for january-june 2023 [Available from:http://www.chinets.com/Document/Index?pageIndex=0] . Accessed September 22, 2023.

[5] Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019 Jan;39(1):10–39.

[6] Yu XB, Zhang XS, Wang YX, et al. Population pharmacokinetics of colistin sulfate in critically ill patients: exposure and clinical efficacy. Front Pharmacol. 2022 Jun 16;13:915958.

[7] Chen N, Guo J, Xie J, et al. Population pharmacokinetics of polymyxin B: a systematic review. Ann Transl Med. 2022 Feb;10(4):231.

[8] Fan Y, Li Y, Chen Y, et al. Pharmacokinetics and pharmacodynamics of colistin methanesulfonate in healthy Chinese subjects after multi-dose regimen. Antibiotics (Basel). 2022 Jun 14;11(6):798.

[9] Hao M, Yang Y, Guo Y, et al. Combination regimens with colistin sulfate versus colistin sulfate monotherapy in the treatment of infections caused by carbapenemresistant gram-negative bacilli. Antibiotics (Basel). 2022 Oct 19;11(10):1440.

[10] Kaye KS, Marchaim D, Thamlikitkul V, et al. Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evid. 2023 Jan;2(1).

[11] Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing M100. 32nd ed.;2022. The last visit was on . Accessed September 22, 2023.

[12] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184.

[13] Shields RK, Nguyen MH, Chen L, et al. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02497, 17.

[14] Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618.

[15] Liu X, Chu Y, Yue H, et al. Risk factors for and clinical outcomes of ceftazidime-avibactam-resistant carbapenem-resistant Klebsiella pneumoniae nosocomial infections: a single-center retrospective study. Infection. 2022 Oct;50(5):1147–1154.

[16] Zhang P, Shi Q, Hu H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 2020 Jan;26(1):124.e1–124.e4.

[17] Han R, Shi Q, Wu S, et al. China antimicrobial surveillance network (CHINET) study group. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020 Jul 3;10:314.

[18] Gaibani P, Re MC, Campoli C, Viale PL, Ambretti S. Bloodstream infection caused by KPCproducing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization. Clin Microbiol Infect. 2020;26(4):516. e1-e4.

[19] Li X, Zhang J, Yang C, et al. Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain. Microbiol Spectr. 2022;10(4): e0095522.

[20] Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38:2275–2281.

[21] Chen YB, Ji JY, Liu ZY, et al. Annual report of drug resistance surveillance of bacterial infections in China. Chin J Clin Infect Dis. 2023;16(1):33–47 [in Chinese].

[22] Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023;18:ciad428.

[23] Fang J, Li H, Zhang M, et al. Efficacy of ceftazidime-avibactam versus polymyxin B and risk factors affecting clinical outcomes in patients with carbapenem-resistant Klebsiella pneumoniae infections a retrospective study. Front Pharmacol. 2021 Dec 10;12:780940.

[24] Hakeam HA, Alsahli H, Albabtain L, et al. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021 Aug;109:1–7.

[25] Yu W, Luo Q, Shen P, et al. New options for bloodstream infections caused by colistin-or ceftazidime/avibactam-resistant Klebsiella pneumoniae. Int J Antimicrob Agents. 2021 Dec;58(6):106458.

[26] Papp-Wallace KM, Zeiser ET, Becka SA, et al. Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa. J Infect Dis. 2019 Jul 19;220(4):666–676.

[27] Montero MM, Domene Ochoa S, López-Causapé C, et al. Time-kill evaluation of antibiotic combinations containing ceftazidime-avibactam against extensively drug-resistant Pseudomonas aeruginosa and their potential role against ceftazidime-avibactam-resistant isolates. Microbiol Spectr. 2021 Sep 3;9(1):e0058521.

[28] Feng K, Jia N, Zhu P, et al. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine-and New Delhi metallo-β-lactamases. J Antimicrob Chemother. 2021 Oct 11;76(11):2875–2883.

[29] Ding L, Shen S, Han R, et al. Ceftazidime-avibactam in combination with imipenem as salvage therapy for ST11 KPC-33-Producing Klebsiella pneumoniae. Antibiotics (Basel). 2022 Apr 29;11(5):604.

[30] Wang L, Shen W, Zhang R, et al. Identification of a novel ceftazidime-avibactamresistant KPC-2 variant, KPC-123, in Citrobacter koseri following ceftazidime-avibactam treatment. Front Microbiol. 2022 Jun 20;13:930777.

[31] Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenemresistant Gram-negative bacteria (CREDIBLE-CR): a randomised, openlabel, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240.

[32] Wang J, Shah BK, Zhao J, et al. Comparative study of poIntell Pharmlymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. BMC Infect Dis. 2023 May 25;23(1):351.

[33] Liu T et al., Risk factors for clinical treatment failure and death in patients with ceftazidime-avibactam-resistant Gramnegative bacteria: A single-centre retrospective analysis, Intell Pharm,

[34] Wang JL, Xiang BX, Song XL, et al. Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: a meta-analysis. World J Clin Cases. 2022 Nov 6;10(31):11466–11485.

RIGHTS & PERMISSIONS

2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.